By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

This new agent, like the other DPP-4 inhibitors, has a mechanism of action that affects both pancreatic ß-cell survival as well as ß-cell secretory function. These medications do not incite ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

A key element is the company’s promising drug, denifanstat, a fatty acid synthase inhibitor, which has shown strong efficacy in Phase 2b trials, particularly among more severe F3 patients. Its unique ...

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

The global proton pump inhibitors (PPIs) market is currently valued at approximately USD 2.8 billion and is projected to grow ...

Patients with sarcoidosis treated with ACE inhibitors had greater mortality risk than those treated with angiotensin receptor blockers.